The autoimmune disease drug developer's series A round has closed at $42.4m after Roche Venture Fund added funding to a first close co-led by AbbVie Ventures.
Pharmaceutical firm Roche’s Venture Fund helped Italy-based autoimmune disease therapy developer Enthera Pharmaceuticals increase its series A round to €35m ($42.4m) yesterday.
The round’s $32.8m first close was co-led by AbbVie’s corporate venturing arm, AbbVie Ventures, with venture capital firm Sofinnova Partners in July 2020, and included Indaco Venture Partners and undisclosed individual investors.
Enthera was founded in 2016 and is developing biologics – medical products derived from living things – to treat autoimmune diseases. It was the first…
